J. Goldman & Co’s Unicycive Therapeutics UNCY Stock Holding History
Bought
Maintained
Sold
Other funds holding UNCY
J. Goldman & Co's UNCY Position: Q3 2026 in Review
J. Goldman & Co reduced its Unicycive Therapeutics (UNCY) stake by 79% in Q3 2026, selling an estimated $1.34M and leaving 69,452 shares worth $326K. The position accounts for 0.01% of the portfolio, ranked #658.
J. Goldman & Co first reported a position in UNCY in Q2 2026 and has held it in 2 quarters since. The position peaked at $1.54M in Q2 2026. 95 funds tracked by Wall St. Rank hold UNCY as of Q3 2026.
- J. Goldman & Co held 69,452 shares of Unicycive Therapeutics worth $326K as of Q3 2026.
- J. Goldman & Co sold 257,893 Unicycive Therapeutics shares in Q3 2026, an estimated $1.34M.
- Unicycive Therapeutics made up 0.01% of J. Goldman & Co's portfolio in Q3 2026, its #658 holding.
- J. Goldman & Co first reported a position in Unicycive Therapeutics in Q2 2026 and has held it in 2 quarters since.
- J. Goldman & Co's Unicycive Therapeutics position peaked at $1.54M in Q2 2026.
- 95 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q3 2026.
Based on J. Goldman & Co's 13F filing for Q3 2026, filed 16 Nov 2026.